Celanese Corporation Q3 2026 Earnings Recap

Celanese shares rose 5.0% after earnings, signaling a positive market response. Investors appear to have welcomed management’s confidence in generating $700–$800 million of free cash flow next year and continued momentum in electronics and healthcare.

Key Takeaways

• Management reiterated a **$700–$800 million free cash flow** range for next year, citing limited need to raise capital spending and opportunities to improve working capital.
• The company expects to shift about **$100 million of costs and interest** into next year, while restructuring cash outlays are expected to decline by **$30–$40 million**.
• Celanese sees electronics and medical continuing as growth areas into 2027, while acknowledging tougher comparisons after strong performance this year.
• In Acetyl Chain, management sees further opportunity in downstream emulsions and powders; any needed investment would remain within its stated **$300–$350 million** capital range.